CT-868

CT-868 is an experimental "biased dual GLP-1 and GIP receptor modulator that exhibits no arrestin coupling or receptor internalization at either receptor". It is developed by Carmot Therapeutics for diabetes and obesity.^[1]^[2]

References[edit]

^ Chakravarthy, Manu; Hernandez, Moises; Elliott, Michael; Macias, Alejandra; Hansen, Stig K.; Hompesch, Marcus (20 June 2023). "774-P: Weight-Independent Effects of CT-868, a Signaling Biased Dual GLP-1/GIP Receptor Modulator, on Glucose Homeostasis in Overweight and Obese Adults with Type 2 Diabetes". Diabetes. 72 (Supplement_1). doi:10.2337/db23-774-P. S2CID 259219222.
^ Rodriguez, Ruben; Tracy, Ted; Morales, Marikris; Hergarden, Anne; Lam, Davina; Krishnan, Shyam; Hansen, Stig K.; Chakravarthy, Manu (20 June 2023). "1649-P: Biased GLP-1 Improves Weight Loss with Additional Benefits on Glucose Homeostasis via Biased GIP in Diabetic Rodent Models". Diabetes. 72 (Supplement_1). doi:10.2337/db23-1649-P. S2CID 259427049.

[1] Chakravarthy, Manu; Hernandez, Moises; Elliott, Michael; Macias, Alejandra; Hansen, Stig K.; Hompesch, Marcus (20 June 2023). "774-P: Weight-Independent Effects of CT-868, a Signaling Biased Dual GLP-1/GIP Receptor Modulator, on Glucose Homeostasis in Overweight and Obese Adults with Type 2 Diabetes". Diabetes. 72 (Supplement_1). doi:10.2337/db23-774-P. S2CID 259219222.

[2] Rodriguez, Ruben; Tracy, Ted; Morales, Marikris; Hergarden, Anne; Lam, Davina; Krishnan, Shyam; Hansen, Stig K.; Chakravarthy, Manu (20 June 2023). "1649-P: Biased GLP-1 Improves Weight Loss with Additional Benefits on Glucose Homeostasis via Biased GIP in Diabetic Rodent Models". Diabetes. 72 (Supplement_1). doi:10.2337/db23-1649-P. S2CID 259427049.

[1]

[2]